Revolution Medicines (NASDAQ:RVMD – Free Report) had its price target lifted by Needham & Company LLC from $31.00 to $35.00 in a research report report published on Wednesday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock. RVMD has been the subject of a number of other reports. HC Wainwright reiterated a buy rating and issued a $32.00 target price on shares of Revolution Medicines in a report on Wednesday, April 12th. JPMorgan Chase & Co. dropped their price target on Revolution Medicines from $38.

https://www.dailypolitical.com/2023/08/06/needham-company-llc-increases-revolution-medicines-nasdaqrvmd-price-target-to-35-00.html

#dailypolitical